register

Human Resources

Talent acquisition and retention: The current state of play in biopharma and medtech sectors

Health Industry Hub | April 6, 2022 |

Human Resources: Evolving employer and employee preferences are significantly influencing talent acquisition and retention outcomes.

Maree Paras, Associate Director, Paras and Partners and Vanessa Meikle, Founder & CEO, Hunton Executive joined Health Industry Hub to deep dive into the current state of talent acquisition and retention across the pharma, medtech and biotech sectors, including “The great resignation or the great rethink?”

According to recent Gartner data, 30% of the skills that were present in job descriptions three years ago will be obsolete in 2022. Vanessa and Maree shared their views on the top workforce skills (soft and hard skills) that are critical in the current ecosystem and the importance of employee investment and commitment in lifelong learning to fulfil what employers define as the “ideal candidate”.

Finally, the duo considered the biggest changes and movements in the current workforce and how this will be evolving in the next 6 months.


News - MedTech & Diagnostics

Hearts4heart takes aim at private system leaving patients to pay the price

Hearts4heart takes aim at health insurers leaving patients to pay the price

Health Industry Hub | September 4, 2026 |

Persistent advocacy by patient groups has prompted the Medical Services Advisory Committee (MSAC) to review the funding gaps for pulsed […]

More


News - MedTech & Diagnostics

Queensland first: Private hospital deploys Abbott's PFA in atrial fibrillation

Queensland first: Private hospitals deploy Abbott’s PFA in atrial fibrillation

Health Industry Hub | September 4, 2026 |

More Australians living with atrial fibrillation (AF) are gaining access to one of the latest advances in heart-rhythm treatment, with […]

More


News - Pharmaceuticals

Five years of HTA reform talk, Now comes the $47 billion question

Five years of HTA reform talk, now comes the $47 billion question

Health Industry Hub | September 4, 2026 |

Medicines Australia has put a $47 billion price tag on what it says Australia must invest to improve equitable access […]

More


News - Pharmaceuticals

New MFN deals raise the stakes for Australia’s delayed HTA reform

New MFN deals raise the stakes for Australia’s delayed HTA reform

Health Industry Hub | September 2, 2026 |

Four months after the US Trump administration concluded what was expected to be the final tranche of drug-pricing agreements with […]

More


This content is copyright protected. Please subscribe to gain access.